Equities

ASP Isotopes Inc

ASPI:NAQ

ASP Isotopes Inc

Actions
Basic MaterialsIndustrial Metals and Mining
  • Price (USD)4.31
  • Today's Change0.45 / 11.66%
  • Shares traded1.29m
  • 1 Year change+883.79%
  • Beta--
Data delayed at least 15 minutes, as of May 15 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ASP Isotopes Inc. is a pre-commercial stage advanced materials company. The Company is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100 and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.

  • Revenue in USD (TTM)433.03k
  • Net income in USD-16.29m
  • Incorporated2021
  • Employees76.00
  • Location
    ASP Isotopes Inc1101 Pennsylvania Avenue Nw, Suite 300WASHINGTON 20004United StatesUSA
  • Phone+1 (202) 756-2245
  • Fax+1 (302) 636-5454
  • Websitehttps://aspisotopes.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Greenwich Lifesciences Inc0.00-8.89m175.66m3.00--26.15-----0.6921-0.69210.000.52150.00----0.00-86.87-36.43-89.30-38.31------------0.00-------13.63------
Galectin Therapeutics Inc0.00-44.81m175.81m14.00---------0.7456-0.74560.00-0.97390.00----0.00-165.97-92.08-394.92-121.97-----------12.726.24-------15.26------
Alpha Tau Medical Ltd0.00-29.16m183.51m121.00--2.17-----0.4203-0.42030.001.210.00----0.00-25.63---26.99--------------0.0623------13.64------
Adverum Biotechnologies Inc0.00-112.90m185.36m121.00--1.02-----10.23-10.230.008.780.00----0.00-41.55-36.39-47.50-39.04-------5,279.60----0.00----17.4324.18---0.0247--
Telomir Pharmaceuticals Inc0.00-13.07m186.69m1.00--52.46-----0.48-0.480.000.1202------0.00-------------------2.400.0285-------1,430.39------
Lifecore Biomedical Inc103.27m-64.24m186.95m459.00------1.81-2.12-3.293.431.160.3911.963.07224,986.90-24.32-5.67-41.13-8.0727.1021.91-62.20-11.901.35-1.050.7495---7.19-27.74-315.07---8.55--
ASP Isotopes Inc433.03k-16.29m188.84m76.00--11.59--436.10-0.5016-0.50160.01310.33310.0216----5,697.76-81.39---109.02--32.09---3,762.82-----251.760.0378-------229.34------
Atossa Therapeutics Inc0.00-30.09m192.97m10.00--2.12-----0.2386-0.23860.000.72640.00----0.00-27.39-29.97-28.80-32.55------------0.00-------11.62---33.90--
Elevation Oncology Inc0.00-39.35m194.51m29.00--2.43-----1.03-1.030.001.470.00----0.00-42.35---46.30-------------12.500.2889------51.93------
Lineage Cell Therapeutics Inc8.00m-23.66m196.35m75.00--2.71--24.53-0.1344-0.13440.04550.38360.0722--57.16106,706.70-21.32-19.53-24.82-22.5991.8889.13-295.30-370.88----0.0018---39.1612.3918.22---27.16--
Fennec Pharmaceuticals Inc21.25m-16.05m198.91m36.00------9.36-0.6042-0.60420.7994-0.430.790.92174.10---59.64-73.43-77.06-84.3294.08---75.50-383.283.27-3.901.63--1,284.50--32.34------
Zevra Therapeutics Inc28.01m-50.90m200.88m65.00--4.11--7.17-1.34-1.340.75131.170.2172--3.47430,876.90-39.48-32.11-47.94-39.8951.11---181.75-128.42----0.4648--170.26---72.00--69.75--
Kodiak Sciences Inc0.00-260.49m201.73m111.00--0.7586-----4.97-4.970.005.060.00----0.00-45.46-31.73-49.53-33.61------------0.00------21.97--134.76--
Data as of May 15 2024. Currency figures normalised to ASP Isotopes Inc's reporting currency: US Dollar USD

Institutional shareholders

4.98%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 20241.01m2.08%
BMO Asset Management Corp.as of 31 Dec 2023339.00k0.70%
Geode Capital Management LLCas of 31 Dec 2023269.84k0.55%
GSA Capital Partners LLPas of 31 Mar 2024254.82k0.52%
Rathbones Investment Management Ltd.as of 31 Dec 2023151.75k0.31%
Citadel Securities LLCas of 31 Dec 2023104.54k0.21%
BlackRock Fund Advisorsas of 31 Mar 202481.97k0.17%
JPMorgan Securities LLC (Investment Management)as of 31 Mar 202477.65k0.16%
Renaissance Technologies LLCas of 31 Dec 202374.77k0.15%
Millennium Management LLCas of 31 Dec 202361.69k0.13%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.